



GIVING HOPE. CHANGING LIVES.




"We are very pleased with the continued momentum

we have experienced since receiving the de novo approval in December 2018. As previously announced, we have raised our outlook for 2019 based on stronger-than-expected sales of Envarsus XR in the US. I am confident in our ability to continue executing on our commercial strategy and expect the second half of 2019 to be just as successful as the first."

Craig A. Colson





CONTENT

4	Highlights for First Half 2019
5	Outlook for 2019
6	Envarsus for Transplantation
10	Financial Statements
12	Financial Highlights
16	Executive Management's and Board of Directors' Statement on the Interim Report
18	Financial Highlights - Quarterly
19	Income Statement and Statement of Comprehensive Income
20	Balance Sheet
22	Cash Flow Statement
23	Statement of Changes in Equity
24	Notes



HIGHLIGHTS FOR FIRST HALF 2019

PRODUCT REVENUE

for the first half of 2019 was USD 33.2 million, an increase of 94% compared to the same period last year.

+94%

US REVENUE

increased 96%
to USD 28.7 million.

+96%

EU REVENUE

increased 76%
to USD 4.4 million.

+76%

NET RESULT

Veloxis reported net income of USD 2.2 million for the first half of 2019 compared with a net loss of USD 5.7 million for the same period in 2018.

+140%*

TRANSPLANT CENTERS

More than 95% of US centers have used Envarsus® since its launch¹



* Calculation based on absolute value.

OUTLOOK FOR 2019

On 22 July 2019, Veloxis revised its 2019 Outlook of revenues to be in the range of USD 69–77 million and operating income before accounting for stock compensation in the range of USD 10–15 million. Veloxis previously reported its 2019 Outlook to be USD 58–68 million for revenues and operating income before accounting for stock compensation in the range of USD 4–10 million.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Veloxis's documents, including this interim report, may contain "forward-looking statements." Words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to, the following:


- statements of targets, plans, objectives or goals for future operations;
- statements containing projections of or targets for revenues, costs, income (or loss), and other financial measures;
- statements regarding future economic performance, future actions and outcome of contingencies;
- statements regarding the assumptions underlying or relating to such statements.

In this interim report, examples of forward- looking statements can be found under the heading Outlook for 2019 and elsewhere.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.

For an overview of some, but not all, of the risks that could adversely affect Veloxis's results or the accuracy of forward-looking statements in this interim report, reference is made to the overview of risk factors in the Risk Management section on pages 32-33 of the Company's 2018 Annual Report.

Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. Unless required by law, Veloxis is under no duty and undertakes no obligation to update or revise any forward- looking statement after the distribution of this interim report whether as a result of new information, future developments or otherwise.



ENVARSUS FOR TRANSPLANTATION

Commercial Update

An important driver of the revenue increase in Q2 2019 was significant uptake of Envarsus in the de novo setting following the US Food & Drug Administration's approval in December 2018 for the use of Envarsus in de novo kidney transplant patients.

In addition to the de novo indication, label enhancements allow promotion of Envarsus for use in special populations that may benefit from increased bioavailability and controlled delivery of tacrolimus.

This continues to be a strong driver of revenue uptake. African-American kidney transplant patients historically experience poorer outcomes compared with other ethnic groups.² These outcomes have been associated in part due to this population's expression of the CYP3A5*1 genotype, which codes for a cytochrome P450 enzyme that metabolizes tacrolimus and is shown to be present in approximately 80% of African-Americans and upwards of 30% of transplant patients, regardless of race.³ Patients expressing this genotype metabolize tacrolimus rapidly and as a result typically require higher tacrolimus doses that may hinder efforts to obtain a therapeutic level, and thereby may potentially increase the risk for organ rejection. Envarsus has demonstrated a unique pharmacokinetic profile in this population, and we believe this data will continue to drive prescription growth in this important and difficult to treat subset of transplant patients.


At the end of Q2 2019, exit market share for Envarsus in the de novo setting was 15.5%.[†] Taken together, the de novo and conversion markets have grown the Envarsus renal prescription market share in the United States to 4.2% in Q2 2019, up from 2.3% in Q2 2018.¹ Veloxis now expects to exit 2019 with a total renal prescription market share of approximately 5.9%.¹

Furthermore, we continued to see a significant proportion of patients who convert to Envarsus transition from generic tacrolimus. In Q2 2019, 88% of patients who converted to Envarsus switched from generic tacrolimus.¹


The large number of patients moving away from generic tacrolimus remains an important demonstration of the benefits Envarsus may offer over existing formulations.

Other key performance indicators in the US market also demonstrated successful adoption of Envarsus within transplant centers. Renal prescriptions of Envarsus grew from 9,957 in Q2 2018 to 19,783 in Q2 2019, representing a growth of 98.7% over the same time period last year.¹ Renal prescribers also showed strong growth from 831 in Q2 2018 to 1,367 in Q2 2019.¹ The significant increase in prescriptions and prescribers demonstrates the broad adoption of Envarsus by the transplant community.

Envarsus XR de novo exit market share¹




[†] Calculation is derived from field intelligence regarding the percentage of de novo population that is being initiated on Envarsus therapy at centers with a de novo protocol in place.




An equally important measurement of potential benefit of Envarsus is the patient's ability to stay on the drug after switching from another formulation. Since its launch in 2015, 99% of patients who convert to Envarsus stay on it after conversion.¹


Envarsus XR renal prescription market share¹




Envarsus XR exit renal prescription market share¹



Percentage of patients converted from other formulations of tacrolimus in Q2 2019¹





ENVARUSUS FOR TRANSPLANTATION

About Envarsus

Envarsus is a novel formulation of tacrolimus designed using advanced technology that allows for increased bioavailability and a controlled, smooth delivery, resulting in once-daily dosing, a lower total daily dose requirement, and lower peak concentrations with less fluctuation.

In addition to the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus, Envarsus was FDA-approved for use in de novo kidney transplant patients in December 2018. This means more patients, including hard-to-treat patients such as rapid metabolizers, can benefit from once-daily controlled-release Envarsus. Envarsus is marketed as Envarsus XR® in the United States.

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage, specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the United States through Veloxis Pharmaceuticals, Inc., a wholly owned subsidiary headquartered in Cary, North Carolina. Veloxis has successfully developed Envarsus based on the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company is focused on the direct commercialization of Envarsus in the United States, expansion of partnerships for markets around the world, and acquisition of assets used in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.


For further information, please visit: www.veloxis.com.


Conference Call


A conference call will be held
9 Aug 2019 at 4:00 PM CEST (Denmark);
10:00 AM EST (New York).

To access the live conference call, please dial one of the following numbers:

Confirmation Code: 1794852

 US: +1 917 720 0178

 DK: +45 32 72 75 18

 UK: +44 (0) 203 009 5710

Following the conference call, a recording will be available on the Company's website: <http://www.veloxis.com>.

For More Information Regarding This Interim Report, Please Contact:

Craig A. Collard

President & CEO

Phone: +1.919.591.3090

Email: cac@veloxis.com


Ira Duarte

CFO

Phone: +1.919.591.3090

Email: idu@veloxis.com






FINANCIAL STATEMENTS



12	Financial Highlights
16	Executive Management's and Board of Directors' Statement on the Interim Report
18	Financial Highlights - Quarterly
19	Income Statement and Statement of Comprehensive Income
20	Balance Sheet
22	Cash Flow Statement
23	Statement of Changes in Equity
24	Notes




FINANCIAL STATEMENTS

Financial Highlights

(USD'000)	YTD 2019	YTD 2018	Q2 2019	Q2 2018	Year 2018
Income Statement					
Revenue	33,240	17,161	18,979	9,896	39,494
Production costs	(6,266)	(3,402)	(3,519)	(2,061)	(7,918)
Gross profit	26,974	13,759	15,460	7,835	31,576
Selling, general and administrative costs	(22,932)	(18,275)	(12,523)	(9,163)	(35,611)
Research and development costs	(1,270)	(371)	(673)	(190)	(1,801)
Operating result before stock compensation	5,109	(2,430)	3,962	(169)	(2,006)
Operating result	2,772	(4,887)	2,264	(1,518)	(5,836)
Net financial income / (expenses)	(3,196)	(2,877)	(1,614)	(1,689)	(6,016)
Result before tax	(424)	(7,764)	650	(3,207)	(11,852)
Tax for the period	2,671	2,100	1,486	1,574	6,567
Net result for the period	2,247	(5,664)	2,136	(1,633)	(5,285)
Balance Sheet					
Cash and cash equivalents	31,244	30,783	31,244	30,783	30,520
Total assets	87,548	70,525	87,548	70,525	77,117
Total equity	10,681	2,121	10,681	2,121	4,614
Investment in property, plant and equipment	80	150	4	-	251
Cash Flow Statement					
Cash flow from operating activities	(658)	(10,398)	2,239	(4,675)	(11,265)
Cash flow from investing activities	(80)	(150)	(4)	-	(251)
Cash flow from financing activities	1,483	33,632	583	-	34,371
Cash and cash equivalents at period end	31,244	30,783	31,244	30,783	30,520
Financial Ratios					
Weighted average number of shares	1,723,460,616	1,712,556,763	1,727,894,135	1,712,638,531	1,713,188,778
Average number of employees (FTEs)	59	54	60	54	55
Assets/equity	8.20	33.25	8.20	33.25	16.71
Share price DKK	2.60	0.92	2.60	0.92	2.19

The interim report has not been audited or reviewed by the Company's independent auditors.





FINANCIAL STATEMENTS

(in thousands USD, except share and per share data)

Revenue

For the first half of 2019, Veloxis reached revenue of USD 33,240, an increase of 94%, compared to USD 17,161 in the same period of 2018. The increase was driven by growth in commercial sales of Envarsus XR in the U.S. which increased by 96% to USD 28,740, compared to USD 14,672 for the first half of 2018. Sales to Chiesi Farmaceutici S.p.A ("Chiesi") in Europe were USD 4,371, an increase of 76%, compared to USD 2,483 for the same period in 2018.

In the second quarter of 2019, Veloxis reached revenue of USD 18,979, an increase of 92%, compared to revenue of USD 9,896 for the same period in 2018. The increase was driven by growth in commercial sales of Envarsus in the U.S., which increased by 99% to USD 16,455 compared to USD 8,254 for the second quarter of 2018. Sales to Chiesi in Europe were USD 2,410, an increase of 47%, compared to USD 1,642 for the same period in 2018.

See Revenue Note 2 for more detail.

Selling, General and Administrative Costs

For the first half of 2019, Veloxis's selling, general and administrative costs amounted to USD 22,932, compared to USD 18,275 during the same period in 2018. The increase reflects additional spends in our sales, marketing, and medical affairs departments in our continued effort to maximize the growth of Envarsus.

In the second quarter of 2019, Veloxis's selling, general and administrative costs amounted to USD 12,523, compared to USD 9,163 during the same period in 2018. The increase reflects additional spends in our sales, marketing, and medical affairs departments in our continued effort to maximize the growth of Envarsus.

Compensation Costs

For the first half of 2019, a total of USD 2,337 was recognized as share-based compensation. The cost is included in selling, general and administrative. The comparable cost for 2018 was USD 2,457.

In the second quarter of 2019, a total of 750,000 warrants were canceled, zero expired, and a total of 5,232,034 warrants were exercised. The subscription price for the exercised shares was DKK 0.35 per share of nominal DKK 0.10 (with regard to 1,758,571 shares), and DKK 0.94 per share of nominal DKK 0.10 (with regard to 3,473,463 shares).

On 30 June 2019, there were a total of 200,950,820 warrants outstanding at an average strike price of DKK 1.34. Members of the Board of Directors held 22,351,246 warrants at an average strike price of DKK 1.19. Members of Executive Management held 84,777,196 warrants at an average strike price of DKK 1.32, while other current and former employees held 93,822,378 warrants at an average strike price of DKK 1.39.

Please refer to Veloxis's latest annual report for additional details on the Company's warrant program.

Veloxis Pharmaceuticals A/S has established a change of control bonus plan for its US affiliate, Veloxis Pharmaceuticals Inc. Under the program, designated employees of Veloxis Pharmaceuticals Inc. are eligible to receive one-time change of control bonus payments totaling up to 1.96 percent of the aggregate consideration received by the shareholders of Veloxis Pharmaceuticals A/S in connection with such change of control. This program is in addition to the change of control bonus for members of Executive Management of Veloxis Pharmaceuticals A/S described in Section 4 of the Company's Remuneration Guidelines.

Research & Development Costs

For the first half of 2019, Veloxis's research and development costs amounted to USD 1,270, compared to USD 371 for the same period in 2018.

In the second quarter of 2019, research and development costs were USD 673, compared to USD 190 during the same period in 2018.

Operating Result

Veloxis's operating income for the first half of 2019 was USD 2,772, compared to a loss of USD 4,887 in the corresponding period of 2018.

Financial Expenses

During the first half of 2019, the Company recognized net financial expenses of USD 3,196, compared to net financial expenses of USD 2,877 in the corresponding period of 2018.

Tax for the Period

Tax for the first half of 2019 was a benefit of USD 2,671 primarily related to the revaluation and recognition of further deferred tax assets. As of 30 June 2019, the deferred tax asset was USD 30,744, compared to USD 27,201 at the end of 2018.

Net Result

Veloxis's net result for the first half of 2019 was income of USD 2,247, compared to a net loss of USD 5,664 in the corresponding period of 2018.

Cash Flow

As of 30 June 2019, the balance sheet reflects cash and cash equivalents of USD 31,244, compared to USD 30,520 on 31 December 2018.


Balance Sheet

As of 30 June 2019, total assets were USD 87,548, compared to USD 77,117 at the end of 2018.

Shareholders' equity equaled USD 10,681 as of 30 June 2019, compared to USD 4,614 at the end of 2018.

Significant Risks and Uncertainties

Veloxis faces a number of risks and uncertainties related to operations, research and development, commercial and financial activities. For further information about risks and uncertainties, we refer to the Annual Report for 2018. As of the date of this Interim Report, there have been no significant changes to Veloxis's overall risk profile since the disclosures made in the Risk Management section on pages 32-33 of the Company's 2018 Annual Report.



FINANCIAL STATEMENTS



Executive Management's and Board of Directors' Statement on the Interim Report


The Executive Management and the Board of Directors have considered and adopted the Interim Report for the six months ended 30 June 2019 of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion Executive Management's review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

Copenhagen, 8 August 2019

Executive Management



Craig A. Collard
President & CEO




Ira Duarte
CFO

Board of Directors



Michael T. Heffernan
Chairman



Mette Kirstine Agger
Deputy Chairman



Anders Götzsche
Member




Robert S. Radie
Member



Paul K. Wotton
Member



Lars Kåre Viksmoen
Member



FINANCIAL STATEMENTS


Financial Highlights - Quarterly

(USD'000)	Q2 2019	Q1 2019	Q4 2018	Q3 2018	Q2 2018	Q1 2018
Income Statement						
Revenue	18,979	14,261	11,741	10,592	9,896	7,265
Production costs	(3,519)	(2,747)	(2,646)	(1,869)	(2,061)	(1,342)
Gross profit	15,460	11,514	9,095	8,723	7,835	5,923
Selling, general and administrative costs	(12,523)	(10,409)	(8,956)	(8,381)	(9,163)	(9,111)
Research and development costs	(673)	(597)	(1,301)	(130)	(190)	(180)
Operating result	2,264	508	(1,162)	212	(1,518)	(3,368)
Net financial income / (expenses)	(1,614)	(1,582)	(1,611)	(1,528)	(1,689)	(1,188)
Result before tax	650	(1,074)	(2,773)	(1,316)	(3,207)	(4,556)
Tax for the period	1,486	1,185	1,624	2,843	1,574	526
Net result for the period	2,136	111	(1,149)	1,527	(1,633)	(4,030)
Balance Sheet						
Cash and cash equivalents	31,244	28,394	30,520	30,564	30,783	35,587
Total assets	87,548	78,802	77,117	76,104	70,525	70,357
Share capital	24,574	24,495	24,399	24,317	24,314	24,314
Total equity	10,681	6,264	4,614	4,307	2,121	2,406
Investment in property, plant and equipment	4	76	101	-	-	150
Cash Flow Statement						
Cash flow from operating activities	2,239	(2,897)	(644)	(223)	(4,675)	(5,723)
Cash flow from investing activities	(4)	(76)	(101)	-	-	(150)
Cash flow from financing activities	583	900	730	10	-	33,631
Cash and cash equivalents at period end	31,244	28,394	30,520	30,564	30,783	35,587
Financial Ratios						
Basic EPS	0.00	0.00	(0.00)	0.00	(0.00)	(0.00)
Diluted EPS (DEPS)	0.00	0.00	(0.00)	0.00	(0.00)	(0.00)
Weighted average number of shares EPS	1,727,894,135	1,718,977,836	1,714,897,661	1,712,723,314	1,712,638,531	1,712,474,087
Weighted average number of shares DEPS	1,795,965,014	1,778,776,362	1,714,897,661	1,721,539,307	1,712,638,531	1,712,474,087
Average number of employees (FTEs)	60	58	56	55	54	53
Assets/equity	8.20	12.58	16.71	17.67	33.25	29.25

Income Statement and Statement of Comprehensive Income

Income Statement		Consolidated			
(USD'000)	YTD 2019	YTD 2018	Q2 2019	Q2 2018	Year 2018
Revenue	33,240	17,161	18,979	9,896	39,494
Production costs	(6,266)	(3,402)	(3,519)	(2,061)	(7,918)
Gross profit	26,974	13,759	15,460	7,835	31,576
Selling, general and administrative costs	(22,932)	(18,275)	(12,523)	(9,163)	(35,611)
Research and development costs	(1,270)	(371)	(673)	(190)	(1,801)
Operating result	2,772	(4,887)	2,264	(1,518)	(5,836)
Financial income	201	62	97	(47)	347
Financial expenses	(3,397)	(2,939)	(1,711)	(1,642)	(6,363)
Result before tax	(424)	(7,764)	650	(3,207)	(11,852)
Tax for the period	2,671	2,100	1,486	1,574	6,567
Net result for the period	2,247	(5,664)	2,136	(1,633)	(5,285)
Basic EPS	0.00	(0.00)	0.00	(0.00)	(0.00)
Diluted EPS	0.00	(0.00)	0.00	(0.00)	(0.00)
Weighted average number of shares EPS	1,723,460,616	1,712,556,763	1,727,894,135	1,712,638,531	1,713,188,778
Weighted average number of shares DEPS	1,791,531,495	1,712,556,763	1,795,965,014	1,712,638,531	1,713,188,778

Statement of Comprehensive Income		Consolidated			
(USD'000)	YTD 2019	YTD 2018	Q2 2019	Q2 2018	Year 2018
Net result for the period	2,247	(5,664)	2,136	(1,633)	(5,285)
Other comprehensive income for the period	-	-	-	-	-
Total comprehensive income for the period	2,247	(5,664)	2,136	(1,633)	(5,285)




FINANCIAL STATEMENTS

Balance Sheet

Assets		Consolidated	
(USD'000)	30 June 2019	30 June 2018	31 Dec 2018
Patent rights and software	32	64	48
Intangible assets	32	64	48
Property, plant and equipment	1,628	948	965
Tangible fixed assets	1,628	948	965
Deferred tax asset	30,774	22,364	27,201
Financial assets	30,774	22,364	27,201
Non-current assets	32,434	23,376	28,214
Inventories	8,832	8,645	8,375
Trade receivables	12,637	5,473	6,903
Other receivables	226	1,313	59
Prepayments	2,175	935	3,046
Receivables	15,038	7,721	10,008
Cash	31,244	30,783	30,520
Cash and cash equivalents	31,244	30,783	30,520
Current assets	55,114	47,149	48,903
Assets	87,548	70,525	77,117

Balance Sheet (Continued)

Equity & Liabilities		Consolidated	
(USD'000)	30 June 2019	30 June 2018	31 Dec 2018
Share capital	24,574	24,314	24,399
Special reserve	-	57,804	-
Translation reserves	(4,052)	(4,052)	(4,052)
Retained earnings/loss	(9,841)	(75,945)	(15,733)
Equity	10,681	2,121	4,614
Loan	60,062	59,748	59,905
Other non-current liabilities	480	-	-
Non-current liabilities	60,542	59,748	59,905
Trade payables	1,634	512	1,996
Other payables	14,691	8,144	10,602
Current liabilities	16,325	8,656	12,598
Liabilities	76,867	68,404	72,503
Equity and liabilities	87,548	70,525	77,117




FINANCIAL STATEMENTS

Cash Flow Statement

Consolidated					
(USD'000)	YTD 2019	YTD 2018	Q2 2019	Q2 2018	Year 2018
Operating result	2,772	(4,887)	2,264	(1,518)	(5,836)
Share-based payment	2,337	2,457	1,698	1,349	3,830
Depreciation and amortization	250	93	126	47	193
Changes in working capital	(2,819)	(3,755)	(237)	(2,989)	(1,927)
Cash flow from operating activities before interest	2,540	(6,092)	3,851	(3,111)	(3,740)
Interest paid	(3,197)	(4,306)	(1,611)	(1,564)	(7,516)
Corporate tax paid	(1)	-	(1)	-	(9)
Cash flow from operating activities	(658)	(10,398)	2,239	(4,675)	(11,265)
Purchase of property, plant and equipment	(80)	(150)	(4)	-	(251)
Cash flow from investing activities	(80)	(150)	(4)	-	(251)
Proceeds from bank borrowings	-	60,000	-	-	60,000
Repayment of principal	-	(26,000)	-	-	(26,000)
Cost of borrowings	-	(380)	-	-	(382)
Proceeds from issuance of shares	1,483	12	583	-	753
Cash flow from financing activities	1,483	33,632	583	-	34,371
Increase/(decrease) in cash	745	23,084	2,818	(4,675)	22,855
Cash at beginning of period	30,520	7,766	28,394	35,587	7,766
Exchange gains/(losses) on cash	(21)	(67)	32	(129)	(101)
Cash at end of period	31,244	30,783	31,244	30,783	30,520

Statement of Changes in Equity

Consolidated						
	Number of Shares	Share Capital USD'000	Special Reserves USD'000	Translation Reserves USD'000	Retained Earnings USD'000	Total USD'000
Equity as of 1 January 2018	1,712,438,531	24,311	57,804	(4,052)	(72,747)	5,316
Net result for the period					(5,664)	(5,664)
Total comprehensive income	-	-	-	-	(5,664)	(5,664)
Warrant exercises	200,000	3			9	12
Share-based payment					2,457	2,457
Other transactions	200,000	3	-	-	2,466	2,469
Equity as of 30 June 2018	1,712,638,531	24,314	57,804	(4,052)	(75,945)	2,121
Net result for the period					379	379
Total comprehensive income	-	-	-	-	379	379
Warrant exercises	5,556,817	85			656	741
Share-based payment					1,373	1,373
Transfer to retained earnings			(57,804)		57,804	-
Other transactions	5,556,817	85	(57,804)	-	59,833	2,114
Equity as of 31 December 2018	1,718,195,348	24,399	-	(4,052)	(15,733)	4,614
Net result for the period					2,247	2,247
Total comprehensive income	-	-	-	-	2,247	2,247
Warrant exercises	11,634,209	175			1,308	1,483
Share-based payment					2,337	2,337
Other transactions	11,634,209	175	-	-	3,645	3,820
Equity as of 30 June 2019	1,729,829,557	24,574	-	(4,052)	(9,841)	10,681



FINANCIAL STATEMENTS

(in thousands USD, except share and per share data)

NOTE 1

Accounting Policies

The Interim Report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the Interim Report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' Annual Report for 2018, with the exception of the implementation of IFRS 16 *Leases* as disclosed in the Interim Report for the period 1 January to 31 March 2019.

NOTE 2

Revenue

Revenue was comprised of the following:

	YTD June		Q2	
(USD'000)	2019	2018	2019	2018
Europe	4,371	2,483	2,410	1,642
United States	28,740	14,672	16,455	8,254
RoW	129	6	114	-
Total	33,240	17,161	18,979	9,896

REFERENCES

1. Symphony Health, based on Veloxis market definition, which includes total prescriptions for prescribers with a renal related specialty classification captured within the Symphony Health data set.
2. Taber DJ, Gebregziabher MG, Srinivas TR, et al. African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients. *Pharmacotherapy*. 2015;35(6):569-77.
3. Trofe-Clark J, Brennan DC, West-Thielke P, et al. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. *Am J Kidney Dis*. 2018;71(3):315-326.



Parent Company
Veloxis Pharmaceuticals A/S
c/o Plesner Advokatfirma
Amerika Plads 37
2100 København Ø
Denmark
Email: info@veloxis.com
www.veloxis.com
CVR No.: 26 52 77 67